The current EORTC Melanoma Cooperative Group adjuvant trial programme on malignant melanoma: Prognosis versus efficacy, toxicity and costs

Melanoma Research

Volumn 7, Issue SUPPL. 2, 1997, Pages

  Eggermont, Alexander M M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Adjuvant therapy; Ganglioside; Interferon; Melanoma; Trials

Indexed keywords

ALPHA2A INTERFERON; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GM2;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RISK; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; MELANOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

CANCER VACCINES; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; MELANOMA; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 0030726941     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Slingluff CL, Dodge RK, Stanley WE, Seigler HF. The annual risk of melanoma progression. Implications for the concept of cure. Cancer 1992; 70:1917-1927.
2. Kelly JW, Blois MS, Sagebiel RW. Frequency and duration of patient follow-up after treatment of a primary malignant melanoma. J Am Acad Dermatol 1985; 13:756-760.
3. McCarthy WH, Shaw UM, Thompson JF, Milton GW. Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow-up study. Surg Gynecol Obstet 1988; 166: 497-502.
4. Rogers GS, Kopf AW, Rigel DS Friedman RJ, Levenstein M, Hart RS. Hazard rate analysis in stage I malignant melanoma. Arch Dermatol 1986; 122:999-1002.
5. Cascinelli N, Vaglini M, Nava M, et al. Prognosis of skin melanoma with regional noe metastases (stage II). J Surg Oncol 1984; 25:240-247.
6. Callery G, Cochran AJ, Roe DJ, et al. Factors prognostic for survival in patients with malignant melanoma spread to the regional lymph nodes. Ann Surgery 1982; 196:69-75.
7. Hill GJ II, Moss SE, Golomb FM, et al. DTIC and combination therapy for melanoma, Cancer 1981; 47:2556-2562.
8. Pinsky CM, Oettgen HF. Surgical adjuvant for malignant melanoma. Surg Clin North Am 1981; 61:1259-1266.
9. Veronesi U, Adamus J, Aubert C, et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 1982; 307:913-916.
10. Quirt IC, DeBoer G, Kersey PA, et al. Randomized controlled trial of adjuvant chemoimmunotherapy with DTIC and BCG alter complete excision of primary melanoma with a poor prognosis or melanoma metastases. Can Med Assoc J 1983; 128:929-936.
11. Fisher RJ, Terry WD, Hodes RJ, et al. Adjuvant immunotherapy or chemotherapy for malignant melanoma: preliminary report of the National Cancer Institute randomized clinical trial. Surg Clin North Am 1981; 61:1267-1277.
12. Loutfi A, Shakr A, Jerry M, et al. Double blind randomized prospective trial of levamisole/placebo in stage I cutaneous malignant melanoma. Clin Invest Med 1987; 10:325-328.
13. Tranum BL, Dixon D, Quagliana I, et al. Lack of benefit of adjunctive chemotherapy in stage I malignant melanoma: a Southwest Oncology Group study. Cancer Treat Rep 1987; 71:643-644.
14. Lejeune FJ, Macher E, Kleeberg UR, et al. An assessment of DTIC versus levumisole and placebo in the treatment of high risk stage I patients after removal of a primary melanoma of the skin, a phase III adjuvant study EORTC Protocol 18761. Eur J Cancer Clin Oncol 1988; 24:881-896.
15. Quirt IC, Shelley WE, Pater JL, et al. Improved survival in patients with poor prognosis malignant melanoma treated with adjuvatn levamisole: a phase III study by the National Cancer Institute of Canada clinical trials group. J Clin Oncol 1991; 9:729-735.
16. Spitler LE. A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. J Clin Oncol 1991;9.736-740.
17. Czametzki KM, Macher E, Suciu S, Thomas D, Steerenberg PA, Rümke P. Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus nontrealement in a randomised multicentre study (EORTC Protocol 18781). Eur J Cancer 1993; 29A: 1237-1242.
18. Karakousis CP, Didolkar MS, Lopez. R, et al. Chemoimmunotherapy (DTIC and Corynehacterium parvum) as adjuvant treatment in malignant melanoma. Cancer Treatment Rep 1979; 63:1739-1743.
19. Balch CM, Smalley RV, Bartolucci AA, et al. A randomized prospective clinical trial of adjuvant C. parvum immunotherapy in 260 palients with clinically localized melanoma (stage I): prognostic factors analysis and preliminary results of immunotherapy. Cancer 1982; 49:1079-1084.
20. Thatcher N, Mene A, Banenee SS, et al. Randomized study of Coryne-bacterium parvum adjuvant therapy following surgery for (stage II) malignant melanoma, Br J Surg 1986; 73:111-115.
21. Morton DL, Holmes EC, Eilber FR, et al. Adjuvant immunotherapy: Results of a randomized trial in patients with lymph node metastases. In Immunotherapy of Human Cancer. Edited by Terry WD, Rosenberg SA. New York: Elsevier North Holland, 1982:245-249.
22. Morton DL. Adjuvant immunotherapy of malignant melanoma: status of clinical trials at UCLA, Int J Immunother 1986; 2:31-36.
23. Terry WD, Hodes RJ, Rosenberg SA, et al. Treatment of stage I and II malignant melanoma with adjuvant immunotherapy or chemotherapy: preliminary analysis ot a prospective randomized trial. In Immunotherapy of Human Cancer. Edited by Terry WD, Rosenberg SA. New York: Elsevier North Holland, 1982:252-257.
24. Wallack MK, Sivanandham M, Balch CM, et al. A phase III randomized, double-blind, multiinstitutional trial ot vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer 1995; 75:34-42.
25. Hersey P, Coates P, McCarthy WH. Active immunotherapy follow- ing surgical removal of high risk melanoma. Present status and future prospects. In: Proceedings of the 8th Annual Meeting of the Society for Biological Therapy. Boston, Massachusetts: Society for Biological Therapy; 1993:24.
26. Meyskens PL, Liu PY, Tuthill RJ, et al. Randomized trial of vitamin A versus observation as adjuvant therapy in high-risk primary malignant melanoma: a Southwest Oncology Group study. J Clin Oncol 1994; 12:2060-2065.
27. Meyskens FL, Kopecky KJ, Taylor CW, et al. Randomized trial of adjuvant human interferon-gamma versus observation in high risk cutaneous melanoma: a Southwest Oncology Group Study. J Natl Cancer Inst 1995; 87:1710-1713.
28. Groh JJ, Dreno B, Chastang C, et al. Results of the French multicenter trial on adjuvant therapy with Interferon alfa-2a in resected primary melanoma [abstract]. Proc Am Soc Clin Oncol 1996; 15:1359.
29. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon-α2h adjuvant therapy of high-risk resected curaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14:7-17.
30. Cole BF, Gelber RD, Kirkwood JM, et al. Quality-of-life-adjusted survival analysis of interferon-alfa2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1996; 14:2666-2673.
31. Creagan ET, Dalton RJ, Ahmann DL, et al. Randomized surgical adjuvant clinical trial or recombinant interferon-alfa-2a in selected patients with malignant melanoma. J Clin Oncol 1995; 13:2776-2783.
32. Cascinelli N, Bufalino R, Morabito A, et al. Results of adjuvant Interferon study in WHO melanoma programme [letter]. Lancet 1994; 343:913-914.
33. Cascinelli N: Evaluation of efficacy of adjuvant rIFN-α 2A in regional node metastases [abstract]. Proc Am Soc Clin Oncol 1995; 14: 410.
34. Hamilton WB, Helling F, Lloyd KO, Livingston PO. Ganglioside expression on human malignant melanoma assessed by quantitative immune thin layer chromatography. Int J Cancer 1993:53:566-573.
35. Jones PC, Sze LL, Liu PY, et al. Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J Natl Cancer Inst 1981; 66:249-254.
36. Livingston PO, Ritter G, Srivastava P, et al. Characterization of IgG and IgM antibodies induces in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res 1989; 49:70-15-7050.
37. Livingstone PO, Wong GYC, Adluri S, et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomised trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994; 12:1036-1044.